Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis drug shows promise for kids in Real-World study

NCT ID NCT06142357

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 200 children aged 6 to 17 with moderate-to-severe plaque psoriasis who are taking secukinumab (Cosentyx). Researchers want to see how long patients stay on the drug, how well it controls their psoriasis, and how tolerable it is. The study collects data from the past and tracks patients going forward to get a real-world picture of the treatment's effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Secukinumab (Cosentyx)
What this could lead to
If successful, this study could confirm that secukinumab is a reliable long-term treatment option for children with moderate-to-severe plaque psoriasis.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It also only includes children already prescribed the drug, which may introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

199 people

The number who actually took part.

Started

Dec 2023

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pediatric patients aged ≥6 to \<18 years old with moderate-to-severe plaque psoriasis after failure/intolerance of frontline treatment in routine clinical practice.

Ages

6 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent and legal representative's permission for study participation obtained prior to beginning of participation in the study. 2. Age ≥6 to \<18 years old. 3. Established diagnosis of active moderate-to-severe plaque psoriasis defined as a PASI score ≥ 10, body surface area (BSA) involvement of ≥10% and PGA score ≥ 3 only or with concomitant psoriatic arthritis. 4. Failure or intolerance of prior psoriasis treatment. 5. Patient was prescribed with secukinumab within 4-16 weeks before inclusion. 6. Decision for secukinumab prescription was made by the attending physician according to the approved national label during routine clinical practice, regardless of this non-interventional study conduct. Exclusion Criteria: 1. Known or suspected severe hypersensitivity for secukinumab, formulation excipients, or injection device components (i.e., latex). 2. History of chronic recurrent infection. 3. Clinically significant infection exacerbation, including active tuberculosis. 4. Age \<6 years or ≥18 years. 5. Pregnancy and breastfeeding. 6. Patients participating in parallel in an interventional clinical trial. 7. Patients participating in parallel in other Novartis-sponsored non-interventional study generating primary data for secukinumab. 8. Patients within the safety follow-up phase of interventional study. 9. Active inflammatory bowel disease at inclusion. 10. Patients who received any vaccine within 4 weeks prior to secukinumab initiation. 11. Any medical or psychological condition in the investigator's opinion which may prevent the study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate to severe plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate to severe plaque psoriasis

Contacts and locations

Locations

  • Novartis Investigative Site

    Chelyabinsk, 454048, Russia

  • Novartis Investigative Site

    Grozny, 364022, Russia

  • Novartis Investigative Site

    Izhevsk, 426009, Russia

  • Novartis Investigative Site

    Kazan', 420012, Russia

  • Novartis Investigative Site

    Kemerovo, 650025, Russia

  • Novartis Investigative Site

    Moscow, 105007, Russia

  • Novartis Investigative Site

    Moscow, 117513, Russia

  • Novartis Investigative Site

    Moscow, 119296, Russia

  • Novartis Investigative Site

    Moscow, 119435, Russia

  • Novartis Investigative Site

    Mytishchi, 141009, Russia

  • Novartis Investigative Site

    Nizhny Novgorod, 603950, Russia

  • Novartis Investigative Site

    Rostov-on-Don, 344022, Russia

  • Novartis Investigative Site

    Tolyatti, 445846, Russia

  • Novartis Investigative Site

    Tula, 300053, Russia

  • Novartis Investigative Site

    Ufa, 450000, Russia

  • Novartis Investigative Site

    Yakutsk, 677000, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.